2011) (Table 1), increasing from 0.5% in children of less than 1 year of age to 1% in children of 15 years of age and further expanding to 2.1% in 512 year olds
Two additional Phase 3 oral assets are particularly useful to watch because they represent next entrants rather than franchise conversions: HDM1002 (conveglipron) HDM1002 is being positioned publicly as a selective oral small-molecule GLP-1R agonist for type 2 diabetes and obesity
Potential drug interactions have not been evaluated
It turns out that scientists were trying to figure out diabetes, and instead, they found a way to slim us all down
Impingement , which happens when theres less space in the shoulder joint often because of anatomy leading to irritation as the tendons and nearby structures rub against each other
This includes personalized dietary guidance, tailored physical activity plans, and behavioral strategies to support your journey